17847-40-4

Basic information

• Product Name: (3,4-DICHLORO-PHENYL)-ETHYL-AMINE
• Synonyms: (3,4-DICHLORO-PHENYL)-ETHYL-AMINE;3,4-DICHLORO-N-ETHYLBENZENAMINE;N-Methyl-3,4-dichlorobenzenemethanamine;Benzenamine,3,4-dichloro-N-ethyl-
• CAS NO: 17847-40-4
• Molecular Formula: C₈H₉Cl₂N
• Molecular Weight: 190.07
• Mol File: 17847-40-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3,4-DICHLORO-PHENYL)-ETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-DICHLORO-PHENYL)-ETHYL-AMINE(17847-40-4)
• EPA Substance Registry System: (3,4-DICHLORO-PHENYL)-ETHYL-AMINE(17847-40-4)

Safety Data

• Hazardous Substances Data: 17847-40-4(Hazardous Substances Data)

Usage

General Description

(3,4-DICHLORO-PHENYL)-ETHYL-AMINE, also known as 3,4-dichlorophenethylamine, is a chemical compound with the molecular formula C8H10Cl2N. It is a derivative of phenethylamine and is structurally similar to amphetamine. The compound has been studied for its potential use as a pharmaceutical agent, particularly in the treatment of neurological and psychiatric disorders. It exhibits psychoactive properties and has been suggested to have potential as a psychotherapeutic aid. However, its use and safety profile have not been thoroughly researched, and further studies are needed to determine its efficacy and potential for therapeutic use.

Upstream product

• 2150-93-8 N-(3,4-dichlorophenyl)acetamide 
• 95-76-1 m,p-dichloroaniline 

Downstream Products

• 55239-41-3 C₉H₈Cl₃NO 
• 15533-87-6 N-Propionyl-N-aethyl-3,4-dichlor-anilin 
• 16505-71-8 N-Acetyl-N-aethyl-3,4-dichlor-anilin 
• 16505-72-9 N-Butyryl-N-aethyl-3,4-dichlor-anilin 
• 67103-23-5 (3,4-Dichloro-phenyl)-ethyl-carbamic acid 3-prop-2-ynyloxycarbonylamino-phenyl ester 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Unusual reactivity of zinc borohydride - Reduction of amides to amines

Zinc borohydride reduces secondary amides to the corresponding N-ethyl amines in excellent yields. The reduction requires only stoichiometric quantities of hydride and does not require the addition of any Lewis acid. The amides are isolated by simple hydrolysis of the reaction mixture.